Alcon information center
-
Certain information on the merger
Merger effective date
April 8, 2011
(23:59 (New York time))Novartis share ISIN CH0012005267 Novartis ADS CUSIP 66987V109 Tax reporting 1099-B Cost basis reporting type Fully taxable Share lot holding period treatment Fair market value Fair market value per Novartis share CHF 50.75 Fair market value per Novartis ADS USD 55.30 Fair market value date Merger effective date Contingent Value Amount per Alcon share (gross)
CHF 7.5150
USD 8.1993Swiss Withholding Tax on Contingent Value Amount
CHF 2.6303
USD 2.8698Contingent Value Amount per Alcon Share (Net)
CHF 4.8847
USD 5.3295Swiss Withholding Tax on nominal value amount increase CHF 0.6792 Grossed-up nominal value amount increase CHF 1.9406 USD/CHF exchange rate 0.91654405 -
Information related to the Extraordinary General Meeting
The Novartis Extraordinary General Meeting took place in Basel, Switzerland on April 8, 2011
View the voting results (0.3 MB)
Minutes of the Extraordinary General Meeting (0.5 MB - German only)
Notice of Extraordinary General Meeting
English
(0.5 MB)German
(0.5 MB)French
(0.5 MB)Brochure “Important Shareholder Information”
English
(1.7 MB)German
(2.2 MB)French
(1.7 MB)For holders of American Depositary Shares (ADSs)
Contact information for merger exchange:
BNY Mellon Shareowner Services
International Phone +1-201-680-6579
Domestic Phone (U.S.) +1-866-401-0295
Globetax
International Phone +1-212-747-9100
Domestic Phone (U.S.) +1-800-845-2416 -
Materials for inspection
Materials for inspection related to the merger of Alcon, Inc. with and into Novartis AG pursuant to article 16 of the Swiss Merger Act.
Brochure “Important Shareholder Information”
English
(1.7 MB)German
(2.2 MB)French
(1.7 MB)The brochure encloses:
- Merger Agreement dated December 14, 2010, entered into by Novartis AG and Alcon, Inc. including the merger balance sheets.
- Joint Merger Report report prepared in connection with the merger between Novartis AG and Alcon, Inc. by the board of directors of both entities.
- Audit Report prepared in connection with the merger between Novartis AG and Alcon, Inc.
Annual Report 2010
Annual Report 2009
Annual Report 2008
The annual financial statements and the annual reports of the last three business years of Alcon, Inc. are available from the Investors and Media section of Alcon's website at http://www.alcon.com.
-
Other Alcon-related information
February 25, 2011
The US Securities and Exchange Commission declared effective the company's registration statement on Form F-4 relating to the merger. Effectiveness of Form F-4 marks a milestone for the closing of the merger, with a last condition receipt of two-thirds approval by the shareholders of both Novartis and Alcon voting at their respective meetings.
Form F-4 as filed with the US Securities Exchange Commission (SEC)
December 15, 2010
Novartis announced it has entered into a definitive agreement with Alcon, Inc. (Alcon; NYSE: ACL) to merge Alcon into Novartis for Novartis shares and a Contingent Value Amount (CVA).
Form 6-K as filed with the US Securities Exchange Commission (SEC)
-
Novartis VWAP calculation for Alcon merger
Day Date Novartis share 1-day VWAP (CHF) Volume USD/CHF exchange rate (at 4:30 pm London time) Novartis share 1-day VWAP (USD) 1 March 24 49.3711 12,713,484 0.9067 54.4514 2 March 25 50.7954 10,638,749 0.9182 55.3206 3 March 28 50.8478 7,644,039 0.9174 55.4260 4 March 29 50.2621 7,502,433 0.9209 54.5793 5 March 30 50.2343 7,419,763 0.9225 54.4545 6 March 31 49.9137 10,253,559 0.9161 54.4850 7 April 1 49.8603 9,619,468 0.9279 53.7346 8 April 4 50.0069 8,083,585 0.9228 54.1904 9 April 5 50.8554 9,819,465 0.9247 54.9966 10 April 6 50.7545 6,585,874 0.9175 55.3183 Novartis Share Value1,2 54.6738 Exchange Ratio1 2.9228 Contingent Value Amount1,3 8.20 1Indicates a term defined in the Merger Agreement
2Shown rounded to four decimal places
3Shown rounded to nearest cent
